BIO.B vs. BIO, TXG, OLK, RVTY, AVTR, WAT, ILMN, PEN, CERE, and LEGN
Should you be buying Bio-Rad Laboratories stock or one of its competitors? The main competitors of Bio-Rad Laboratories include Bio-Rad Laboratories (BIO), 10x Genomics (TXG), Olink Holding AB (publ) (OLK), Revvity (RVTY), Avantor (AVTR), Waters (WAT), Illumina (ILMN), Penumbra (PEN), Cerevel Therapeutics (CERE), and Legend Biotech (LEGN). These companies are all part of the "medical" sector.
Bio-Rad Laboratories (NYSE:BIO) and Bio-Rad Laboratories (NYSE:BIO.B) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.
Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.
In the previous week, Bio-Rad Laboratories had 12 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 18 mentions for Bio-Rad Laboratories and 6 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 0.45 beat Bio-Rad Laboratories' score of 0.43 indicating that Bio-Rad Laboratories is being referred to more favorably in the news media.
65.2% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 0.0% of Bio-Rad Laboratories shares are held by institutional investors. 17.1% of Bio-Rad Laboratories shares are held by insiders. Comparatively, 28.4% of Bio-Rad Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Bio-Rad Laboratories has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.
Bio-Rad Laboratories presently has a consensus price target of $461.00, suggesting a potential upside of 63.48%. Given Bio-Rad Laboratories' higher possible upside, equities research analysts clearly believe Bio-Rad Laboratories is more favorable than Bio-Rad Laboratories.
Bio-Rad Laboratories received 237 more outperform votes than Bio-Rad Laboratories when rated by MarketBeat users. Likewise, 64.99% of users gave Bio-Rad Laboratories an outperform vote while only 57.60% of users gave Bio-Rad Laboratories an outperform vote.
Summary
Bio-Rad Laboratories beats Bio-Rad Laboratories on 8 of the 11 factors compared between the two stocks.
Get Bio-Rad Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIO.B and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIO.B and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BIO.B vs. The Competition
Bio-Rad Laboratories Competitors List
Related Companies and Tools
